Juno Therapeutics, Inc. (NASDAQ:JUNO) Analyst Ratings as of May 3, 2018

May 3, 2018 - By Madeline Delgado

Juno Therapeutics, Inc. (NASDAQ:JUNO) Corporate Logo
Big Money Sentiment increased to 1.67 in 2017 Q4. It has change of 0.23, from 2017Q3’s 1.44. The ratio increased due to Juno Therapeutics, Inc. positioning: 25 sold and 47 reduced. 45 funds took positions and 75 increased positions. Investors holded 66.13 million in 2017Q3 but now own 68.38 million shares or 3.41% more.
Dekabank Deutsche Girozentrale has invested 0.01% in Juno Therapeutics, Inc. (NASDAQ:JUNO). Pnc Gru has invested 0% in Juno Therapeutics, Inc. (NASDAQ:JUNO). Global X Mngmt Ltd Liability Co accumulated 2,282 shs. Rhumbline Advisers invested in 0.01% or 61,919 shs. D E Shaw And has 0.02% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO). Voya Investment Management Limited Liability Corp has 18,479 shs. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0.01% or 17,196 shs. Quantbot L P reported 0.01% stake. Marshall Wace Llp stated it has 0.01% of its capital in Juno Therapeutics, Inc. (NASDAQ:JUNO). Schwab Charles Invest Management Inc accumulated 378,195 shs. Moreover, Kistler has 0.01% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO) for 302 shs. Credit Suisse Ag accumulated 260,490 shs. Ameriprise invested 0% of its capital in Juno Therapeutics, Inc. (NASDAQ:JUNO). Fairfield Bush And holds 0.23% or 18,075 shs. M&T Savings Bank has 14,015 shs for 0% of their capital.

Juno Therapeutics, Inc. (NASDAQ:JUNO) Ratings Coverage

A total of 12 analysts rate Juno Therapeutics (NASDAQ:JUNO) as follows: 0 “Buy”, 12 “Hold” and 0 “Sell”. Тherefore 0 are bullish. (NASDAQ:JUNO) has 14 ratings reports on May 3, 2018 according to StockzIntelligence. On Wednesday, January 17 Wedbush downgraded Juno Therapeutics, Inc. (NASDAQ:JUNO) rating. Wedbush has “Hold” rating and $70.0 target. On Tuesday, January 23 the stock has “Hold” rating by Maxim Group. On Monday, January 22 Needham downgraded the shares of JUNO in report to “Hold” rating. The stock rating was initiated by Needham with “Buy” on Friday, January 5. On Wednesday, January 24 the firm has “Hold” rating given by Standpoint Research. On Tuesday, January 23 Leerink Swann downgraded Juno Therapeutics, Inc. (NASDAQ:JUNO) to “Market Perform” rating. On Wednesday, January 24 Barclays Capital downgraded the shares of JUNO in report to “Equal-Weight” rating. On Wednesday, January 17 the rating was maintained by Wells Fargo with “Hold”. On Monday, January 22 the firm has “Hold” rating by Guggenheim given. On Tuesday, December 12 the company was downgraded by Wells Fargo. Listed here are Juno Therapeutics, Inc. (NASDAQ:JUNO) PTs and latest ratings.

24/01/2018 Broker: Standpoint Research Old Rating: Buy New Rating: Hold Downgrade
24/01/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade
23/01/2018 Broker: Maxim Group Old Rating: Buy New Rating: Hold Downgrade
23/01/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Market Perform Old Target: $56 New Target: $87 Downgrade
23/01/2018 Broker: SunTrust Old Rating: Buy New Rating: Hold Downgrade
22/01/2018 Broker: Raymond James Rating: Hold Downgrade
22/01/2018 Broker: Needham Rating: Hold Downgrade
22/01/2018 Broker: Guggenheim Rating: Hold Downgrade
17/01/2018 Broker: Citigroup Rating: Hold New Target: $81.0 Downgrade
17/01/2018 Broker: Wedbush Rating: Hold New Target: $70.0 Downgrade

The last price was $86.96.Since May 3, 2017 it’s 0.00% down thus . JUNO underperformed the S&P 500 by 11.55%.

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell cancer immunotherapies.The company has $10.10 billion market cap. The firm develops cell cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.Currently it has negative earnings. The Company’s CD19 product candidates include JCAR017 that is in Phase I/II trials for adults with relapsed or refractory B cell aggressive non-Hodgkin lymphoma (NHL) and pediatric patients with r/r B cell acute lymphoblastic leukemia (ALL); JCAR014, which is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies; and JCAR015 that is in Phase II trials for adult patients with r/r ALL.

Juno Therapeutics, Inc. (NASDAQ:JUNO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: